AASLD	American Association for the Study of Liver Diseases
AE	Adverse Events
AH	Arterial Hypertension
AZA	Azathioprine
bDNA	Branched DNA signal amplification
CI	Confidence intervals
CKD	Chronic kidney disease
CKD-EPI	Chronic kidney disease epidemiology collaboration equation
CMV	Cytomegalovirus
CNI	Calcineurin inhibitor
DAA	Direct-acting antiviral agent
DCV	Daclatasvir
DDI	Drug-drug interaction
DM	Diabetes mellitus
DSV	Dasabuvir
eGFR	Estimated glomerular filtration rate
EOT	End-of-treatment
ESRD	End-stage renal disease
FDA	Food and Drug administration
GI	Gastrointestinal
GN	Glomerulonephritis
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HD	Haemodialysis
IDSA	Infectious Disease Society of America
IFN	Interferon
IQR	Interquartile range
IRB	Institutional review board
ITT	Intention-to-treat
KDIGO	Kidney Disease: Improving Global Outcomes
LDV	Ledipasvir
LT	Liver transplant
MMF	Mycophenolate mofetil
mTOR	Mammalian target of rapamycin
NA	Not available
NAT	Nucleic acid testing
OBV	Ombitasvir
OPTN	Organ Procurement Transplantation Network
OR	Odds ratio
PCR	Polymerase chain reaction
PegIFN	Pegylated interferon
PHS	Public health service
PI	Protease inhibitors
PTV	Paritaprevir
R	Ritonavir
RBV	Ribavirin
RR	Relative risk
RT	Renal transplant
RRT	Renal replacement therapy
SAE	Serious adverse event
SOF	Sofosbuvir
SVR	Sustained Virological Response
TAC	Tacrolimus
TMA	Transcription-mediated amplification
UNOS	United Network for Organ Sharing
USA	United States of America
VEL	Velpatasvir
WKS	Weeks
W12	12 weeks after antiviral therapy ended